Back to Report Store Home

Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

  • Published: Dec-2012
  • Report Code: GBIHC287MR
  • Report Format: pdf

Description

List of Tables

Table 1: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue ($m), 2004–2011

Table 2: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2011–2018

Table 3: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue by Geography ($m), 2004–2011

Table 4: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2004–2018

Table 5: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004–2011

Table 6: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2011–2018

Table 7: Liver Cancer Therapeutics Market to 2018, Nexavar, Clinical Trial Results

Table 8: Liver Cancer Therapeutics Market, Nexavar, Adverse Reactions Reported in Clinical Trial

Table 9: Liver Cancer Therapeutics Market, Nexavar, Approval History

Table 10: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004–2011

Table 11: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2011–2018

Table 12: Liver Cancer Therapeutics Market, US, Revenue ($m), 2004–2011

Table 13: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2011–2018

Table 14: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004–2011

Table 15: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2011–2018

Table 16: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004–2011

Table 17: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2011–2018

Table 18: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue ($m), 2004–2011

Table 19: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2011–2018

Table 20: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2004–2011

Table 21: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2011–2018

Table 22: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004–2011

Table 23: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2011–2018

Table 24: Liver Cancer Therapeutics Market, Japan, Revenue ($m), 2004–2011

Table 25: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2011–2018

Table 26: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004–2011

Table 27: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011–2018

Table 28: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004–2011

Table 29: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2011–2018

Table 30: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012

Table 31: Liver Cancer Therapeutics Market, Global, Phase III Pipeline

Table 32: Liver Cancer Therapeutics Market, Global, Phase II/III Pipeline

Table 33: Liver Cancer Therapeutics Market, Global, Phase II Pipeline

Table 34: Liver Cancer Therapeutics Market, Global, Phase I/II Pipeline

Table 35: Liver Cancer Therapeutics Market, Global, Phase I Pipeline

Table 36: Liver Cancer Therapeutics Market, Global, Preclinical, 2012

Table 37: Liver Cancer Therapeutics Market, Global, Discovery, 2012

Table 38: Liver Cancer Therapeutics Market, Global, Bayer AG, Pharmaceutical Brands, 2012

Table 39: Liver Cancer Therapeutics Market, Global, Dainippon Sumitomo Pharma, Pharmaceutical Brands, 2012

Table 40: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007–2012

Table 41: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007–2012

Table 42: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007–2012

Table 43: Liver Cancer Therapeutics Market, Global, Major M&A Deals, 2007–2012

Table 44: Liver Cancer Therapeutics Market, Global, Major Licensing Agreement Deals, 2007–2012

Table 45: Liver Cancer Therapeutics Market, Global, Major Co-Development Deals, 2007–2012

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3500
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7000
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$10500
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards